SOURCE: Nabsys

Nabsys

May 24, 2017 08:01 ET

Nabsys Demonstrates High-Definition Whole Genome Mapping Performance Capturing Structural Variants in Microbial and Human Genomes, Plans Beta Program

Talks and Papers Previewed at PMWC 2017 and SFAF Conferences Advance Nabsys' Mission to Democratize Structural Information

PROVIDENCE, RI--(Marketwired - May 24, 2017) - Nabsys, a genomics company pioneering high-definition mapping of genomes using high-resolution, high-speed nanodetectors, today shared performance of its new electronic HD-Mapping™ platform and its ability to identify structural variation in both microbial and human genomes. The company also confirmed it is preparing for a beta program.

In a talk titled "Whole Genome Mapping...Now in HD," Nabsys founder and CEO Dr. Barrett Bready revealed the advantages of using solid-state nanodetectors to build high-definition whole genome maps and analyze genomic structural variation (genomic changes larger than ~100 base pairs). He explained that despite advances in next generation sequencing technologies, limitations imposed by short read lengths of leading sequencing technologies combined with the repetitive nature of genomes present challenges for genome assembly and analysis. Longer range techniques such as optical mapping provide information over a larger scale, but lack resolution.

"Nabsys' significant progress this past year puts us in a strong position to launch a beta program to select labs early next year with a full commercial launch to follow," Dr. Bready said. "By avoiding optics and going completely electronic and semiconductor-based, the platform will enjoy more than an order of magnitude cost advantage over optical mapping for both the instrument and consumables. We want to democratize genomic structural variation. Our goal by next year is to enable individual researchers to do whole genome structural variation analysis on their samples at their own benchtops."

At PMWC, Dr. Bready showed data from pre-published papers titled "High-Definition Electronic Genome Maps from Single Molecule Data" and "Automated Structural Variant Verification in Human Genomes using Single-Molecule Electronic DNA Mapping." The papers are available for download from the company's website.

Dr. Bready's talk follows presentations entitled, "High Density Electronic Maps to Verify Structural Variations in Human Genomes" and "De Novo Assembly of High Density Electronic Maps Reveal Structural Diversity in Bordetella pertussis" (better known as whooping cough) at the 12th Annual Sequencing, Finishing, and Analysis in the Future Conference. Nabsys collaborated with researchers at the Centers for Disease Control and Prevention (CDC) to create highly accurate whole genome electronic maps of pathogenic strains of B. pertussis enabling a level of structural analysis unavailable to existing mapping technologies. The precision and accuracy of Nabsys HD-Mapping™ allowed for distinction between highly related strains and identified structural differences which may contribute to observed variation in virulence and vaccine avoidance characteristics among the strains.

Nabsys HD-Mapping
The Nabsys HD-Mapping platform works by adding sequence-specific tags to long DNA molecules. These molecules are then driven through the nanodetectors at high velocity using a combination of electrophoretic and hydrodynamic control. The detector reports the locations of the sequence-specific tags on the molecules. The information is then analyzed by the Nabsys suite of software tools and can be used for the following applications:

  • Analysis of structural variation
  • De novo sequencing/assembly of genomes
  • Validation of contigs produced from NGS data
  • Characterization of sample heterogeneity

About Nabsys
Nabsys is a privately held company that develops semiconductor-based tools for better genomic analysis. The company has pioneered the technology of electronic high-definition mapping that is capable of analyzing entire genomes in very large fragments (100,000 bp and higher) traveling at high velocity (greater than 1 million base pairs per second). Nabsys was the first company to receive a "1000 Genome" award from the National Human Genome Research Institute of the National Institutes of Health for an electronic approach to DNA analysis. For more information, please visit http://www.nabsys.com or contact us at info@nabsys.com. Stay connected with Nabsys on Twitter: https://twitter.com/nabsys

Contact Information

  • Media Contact:
    Pamela Mahoney
    BlueChair Group
    (408) 674-6997
    Email Contact